These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 27403880)

  • 21. Deferoxamine inhibits microglial activation, attenuates blood-brain barrier disruption, rescues dendritic damage, and improves spatial memory in a mouse model of microhemorrhages.
    He XF; Lan Y; Zhang Q; Liu DX; Wang Q; Liang FY; Zeng JS; Xu GQ; Pei Z
    J Neurochem; 2016 Aug; 138(3):436-47. PubMed ID: 27167158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice.
    Khamseekaew J; Kumfu S; Wongjaikam S; Kerdphoo S; Jaiwongkam T; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    Eur J Pharmacol; 2017 Mar; 799():118-127. PubMed ID: 28192097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
    Sridharan K; Sivaramakrishnan G
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and future treatment strategies for iron overload cardiomyopathy.
    Wongjaikam S; Kumfu S; Chattipakorn SC; Fucharoen S; Chattipakorn N
    Eur J Pharmacol; 2015 Oct; 765():86-93. PubMed ID: 26291660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.
    Kuo KH; Mrkobrada M
    Hemoglobin; 2014; 38(6):409-21. PubMed ID: 25307964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
    Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus.
    Neupane GP; Kim DM
    Transfusion; 2009 Aug; 49(8):1762-9. PubMed ID: 19413741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial calcium uniporter blocker effectively prevents brain mitochondrial dysfunction caused by iron overload.
    Sripetchwandee J; Sanit J; Chattipakorn N; Chattipakorn SC
    Life Sci; 2013 Mar; 92(4-5):298-304. PubMed ID: 23333832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
    Otto-Duessel M; Brewer C; Gonzalez I; Nick H; Wood JC
    Acta Haematol; 2008; 120(2):123-8. PubMed ID: 19018129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
    Al-Rousan RM; Rice KM; Katta A; Laurino J; Walker EM; Wu M; Triest WE; Blough ER
    Transl Res; 2011 Jun; 157(6):368-77. PubMed ID: 21575921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study.
    Sriwichaiin S; Thiennimitr P; Thonusin C; Sarichai P; Buddhasiri S; Kumfu S; Nawara W; Kittichotirat W; Fucharoen S; Chattipakorn N; Chattipakorn SC
    Life Sci; 2022 Oct; 307():120871. PubMed ID: 35952729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.
    Kalanaky S; Hafizi M; Safari S; Mousavizadeh K; Kabiri M; Farsinejad A; Fakharzadeh S; Nazaran MH
    Int J Hematol; 2016 Mar; 103(3):274-82. PubMed ID: 26830968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
    Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
    Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thalassemia: cardiac iron and chelators.
    Gaur A
    Indian Pediatr; 2012 Apr; 49(4):268-9. PubMed ID: 22565070
    [No Abstract]   [Full Text] [Related]  

  • 39. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT; Temraz S; Cappellini MD
    Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chelation of thallium by combining deferasirox and desferrioxamine in rats.
    Saljooghi AS; Babaie M; Mendi FD; Zahmati M; Saljooghi ZS
    Toxicol Ind Health; 2016 Jan; 32(1):83-8. PubMed ID: 24021432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.